Culture-guided treatment approach for Helicobacter pylori infection: Review of the literature

World Journal of Gastroenterology

Volumn 20, Issue 18, 2014, Pages 5205-5211

  Cammarota, Giovanni ^a   Ianiro, Gianluca ^a   Bibbò, Stefano ^a   Di Rienzo, Teresa Antonella ^a   Masucci, Luca ^a   Sanguinetti, Maurizio ^a   Gasbarrini, Antonio ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Antibiotic resistance; Antibiotic susceptibility testing; Culture guided approach; Helicobacter pylori; Personalized therapy

Indexed keywords

ACETYLCYSTEINE; AMOXICILLIN; ANTIINFECTIVE AGENT; BENZOCAINE; BISMUTH; CLARITHROMYCIN; DOXYCYCLINE; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; OMEPRAZOLE; PREBIOTIC AGENT; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; COST EFFECTIVENESS ANALYSIS; DNA POLYMORPHISM; ENDOSCOPY; ERADICATION THERAPY; HELICOBACTER INFECTION; HUMAN; MULTICENTER STUDY (TOPIC); PEPTIC ULCER; PRACTICE GUIDELINE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT FAILURE; UREA BREATH TEST; ANTIBIOTIC RESISTANCE; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFECTS; ECONOMICS; GROWTH, DEVELOPMENT AND AGING; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PREDICTIVE VALUE; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG RESISTANCE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INDIVIDUALIZED MEDICINE; MICROBIAL SENSITIVITY TESTS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84900408430     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i18.5205     Document Type: Article

References (44)

1. Magalhães Queiroz DM, Luzza F. Epidemiology of Helicobacter pylori infection. Helicobacter 2006; 11 Suppl 1: 1-5 [PMID: 16925604 DOI: 10.1111/j.1478-405X.2006.00429.x]
2. Gasbarrini G, Racco S, Franceschi F, Miele L, Cammarota G, Grieco A, Gasbarrini A. [Helicobacter pylori infection: from gastric to systemic disease]. Recenti Prog Med 2010; 101: 27-33 [PMID: 20391683]
3. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781 [PMID: 17170018 DOI: 10.1136/gut.2006.101634]
4. Georgopoulos SD, Papastergiou V, Karatapanis S. Current options for the treatment of Helicobacter pylori. Expert Opin Pharmacother 2013; 14: 211-223 [PMID: 23331077 DOI: 10.1517 /14656566.2013.763926]
5. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/ gutjnl-2012-302084]
6. Di Mario F, Cavallaro LG, Scarpignato C. 'Rescue' therapies for the management of Helicobacter pylori infection. Dig Dis 2006; 24: 113-130 [PMID: 16699270 DOI: 10.1159/000090315]
7. De Francesco V, Giorgio F, Ierardi E, Zotti M, Neri M, Milano A, Varasano V, Luzza F, Suraci E, Marmo R, Marone A, Manta R, Mirante VG, de Matthaeis M, Pedroni A, Manes G, Pallotta S, Usai P, Liggi M, Gatto G, Peri V, Sacco R, Bresci G, Monica F, Hassan C, Zullo A. Primary clarithromycin resistance in Helicobacter pylori: the Multicentric Italian Clarithromycin Resistance Observational (MICRO) study. J Gastrointestin Liver Dis 2011; 20: 235-239 [PMID: 21961089]
8. Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20: 280-322 [PMID: 17428887 DOI: 10.1128/CMR.00033-06]
9. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42 [PMID: 22580412 DOI: 10.1136/gutjnl-2012-302254]
10. Seck A, Burucoa C, Dia D, Mbengue M, Onambele M, Raymond J, Breurec S. Primary antibiotic resistance and associated mechanisms in Helicobacter pylori isolates from Senegalese patients. Ann Clin Microbiol Antimicrob 2013; 12: 3 [PMID: 23298145 DOI: 10.1186/1476-0711-12-3]
11. Rajper S, Khan E, Ahmad Z, Alam SM, Akbar A, Hasan R. Macrolide and fluoroquinolone resistance in Helicobacter pylori isolates: an experience at a tertiary care centre in Pakistan. J Pak Med Assoc 2012; 62: 1140-1144 [PMID: 23866399]
12. Zendedel A, Moradimoghadam F, Almasi V, Zivarifar H. Antibiotic resistance of Helicobacter pylori in Mashhad, Iran. J Pak Med Assoc 2013; 63: 336-339 [PMID: 23914633]
13. Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, Shin CM, Park YS, Lee DH, Jung HC. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 2013; 18: 206-214 [PMID: 23241101 DOI: 10.1111/hel.12031]
14. Seo JH, Jun JS, Yeom JS, Park JS, Youn HS, Ko GH, Baik SC, Lee WK, Cho MJ, Rhee KH. Changing pattern of antibiotic resistance of Helicobacter pylori in children during 20 years in Jinju, South Korea. Pediatr Int 2013; 55: 332-336 [PMID: 23279258 DOI: 10.1111/ped.12048]
15. Loffeld RJ, Werdmuller BF. Changes in Antibiotic Susceptibility of Helicobacter pylori in the Course of Eight Years in the Zaanstreek Region in The Netherlands. Gastroenterol Res Pract 2013; 2013: 625937 [PMID: 23573077 DOI: 10.1155/2013/625937]
16. Kupcinskas L, Rasmussen L, Jonaitis L, Kiudelis G, Jørgensen M, Urbonaviciene N, Tamosiunas V, Kupcinskas J, Miciuleviciene J, Kadusevicius E, Berg D, Andersen LP. Evolution of Helicobacter pylori susceptibility to antibiotics during a 10-year period in Lithuania. APMIS 2013; 121: 431-436 [PMID: 23078193 DOI: 10.1111/apm.12012]
17. Selgrad M, Meissle J, Bornschein J, Kandulski A, Langner C, Varbanova M, Wex T, Tammer I, Schlüter D, Malfertheiner P. Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies. Eur J Gastroenterol Hepatol 2013; 25: 1257-1260 [PMID: 23863261 DOI: 10.1097/MEG.0b013e3283643491]
18. Kjøller M, Fischer A, Justesen T. Transport conditions and number of biopsies necessary for culture of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1991; 10: 166-167 [PMID: 2060517]
19. Elizalde JI, Gómez J, Ginès A, Llach J, Piqué JM, Bordas JM, Marco F, Terés J. Biopsy forceps disinfection technique does not influence Helicobacter pylori culture. Am J Gastroenterol 1998; 93: 1450-1452 [PMID: 9732923]
20. Dickey W, Kenny BD, McConnell JB. Effect of proton pump inhibitors on the detection of Helicobacter pylori in gastric biopsies. Aliment Pharmacol Ther 1996; 10: 289-293 [PMID: 8791953]
21. Choi YJ, Kim N, Lim J, Jo SY, Shin CM, Lee HS, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Jung HC. Accuracy of diagnostic tests for Helicobacter pylori in patients with peptic ulcer bleeding. Helicobacter 2012; 17: 77-85 [PMID: 22404437]
22. Rimbara E, Noguchi N, Yamaguchi T, Narui K, Kawai T, Sasatsu M. Development of a highly sensitive method for detection of clarithromycin-resistant Helicobacter pylori from human feces. Curr Microbiol 2005; 51: 1-5 [PMID: 15971095]
23. Kawai T, Yamagishi T, Yagi K, Kataoka M, Kawakami K, Sofuni A, Itoi T, Sakai Y, Moriyasu F, Osaka Y, Takagi Y, Aoki T, Rimbara E, Noguchi N, Sasatsu M. Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities. J Gastroenterol Hepatol 2008; 23 Suppl 2: S171-S174 [PMID: 19120893]
24. Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-180 [PMID: 11860399 DOI: 10.1046/ j.1365-2036.2002.01169.x]
25. Gasbarrini A, Ojetti V, Armuzzi A, Branca G, Canducci F, Torre ES, Candelli M, Pastorelli A, Anti M, Fedeli G, Fadda G, Pola P, Gasbarrini G. Efficacy of a multistep strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 79-83 [PMID: 10632649 DOI: 10.1046/j.1365-2036.2000.00685. x]
26. Cammarota G, Martino A, Pirozzi G, Cianci R, Branca G, Nista EC, Cazzato A, Cannizzaro O, Miele L, Grieco A, Gasbarrini A, Gasbarrini G. High efficacy of 1-week doxycycline-and amoxicillin-based quadruple regimen in a cultureguided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther 2004; 19: 789-795 [PMID: 15043520 DOI: 10.1111/j.1365-2036.2004.01910.x]
27. Gomollón F, Sicilia B, Ducóns JA, Sierra E, Revillo MJ, Ferrero M. Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. Aliment Pharmacol Ther 2000; 14: 1335-1338 [PMID: 11012479 DOI: 10.1046/j.1365-2036.2000.00833.x]
28. Vicente R, Sicilia B, Gallego S, Revillo MJ, Ducóns J, Gomollón F. [Helicobacter pylori eradication in patients with peptic ulcer after two treatment failures: a prospective cultureguided study]. Gastroenterol Hepatol 2002; 25: 438-442 [PMID: 12139836]
29. Cammarota G, Branca G, Ardito F, Sanguinetti M, Ianiro G, Cianci R, Torelli R, Masala G, Gasbarrini A, Fadda G, Landolfi R, Gasbarrini G. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol 2010; 8: 817-820. e3 [PMID: 20478402 DOI: 10.1016/j.cgh.2010.05.006]
30. Yahav J, Samra Z, Niv Y, Evans CT, Passaro DJ, Dinari G, Shmuely H. Susceptibility-guided vs. empiric retreatment of Helicobacter pylori infection after treatment failure. Dig Dis Sci 2006; 51: 2316-2321 [PMID: 17078005 DOI: 10.1007/ s10620-006-9302-2]
31. Fiorini G, Vakil N, Zullo A, Saracino IM, Castelli V, Ricci C, Zaccaro C, Gatta L, Vaira D. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2013; 11: 507-510 [PMID: 23267869 DOI: 10.1016/j.cgh.2012.12.007]
32. Toracchio S, Cellini L, Di Campli E, Cappello G, Malatesta MG, Ferri A, Ciccaglione AF, Grossi L, Marzio L. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 1639-1643 [PMID: 11121913 DOI: 10.1046/ j.1365-2036.2000.00870.x]
33. Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, Perez-Gallardo B, Dueñas-Sadornil C, Hernandez-Alonso M, Gonzalez-Garcia G, Mateos-Rodriguez JM, Fernandez-Bermejo M, Gisbert JP. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. Helicobacter 2012; 17: 269-276 [PMID: 22759326 DOI: 10.1111/j.1523-5378.2012.00947.x]
34. Cosme A, Montes M, Martos M, Gil I, Mendarte U, Salicio Y, Piñeiro L, Recasens MT, Ibarra B, Sarasqueta C, Bujanda L. Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. Clin Microbiol Infect 2013; 19: 379-383 [PMID: 22512623 DOI: 10.1111/j.1469-0691.2012.03844.x]
35. Furuta T, Shirai N, Kodaira M, Sugimoto M, Nogaki A, Kuriyama S, Iwaizumi M, Yamade M, Terakawa I, Ohashi K, Ishizaki T, Hishida A. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007; 81: 521-528 [PMID: 17215846]
36. Breuer T, Graham DY. Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective? Am J Gastroenterol 1999; 94: 725-729 [PMID: 10086658 DOI: 10.1111/j.1572-0241.1999.00943.x]
37. Romano M, Marmo R, Cuomo A, De Simone T, Mucherino C, Iovene MR, Montella F, Tufano MA, Del Vecchio Blanco C, Nardone G. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 2003; 1: 273-278 [PMID: 15017668 DOI: 10.1016/S1542-3565(03)00131-9]
38. An B, Moon BS, Kim H, Lim HC, Lee YC, Lee G, Kim SH, Park M, Kim JB. Antibiotic resistance in Helicobacter pylori strains and its effect on H. pylori eradication rates in a single center in Korea. Ann Lab Med 2013; 33: 415-419 [PMID: 24205490 DOI: 10.3343/alm.2013.33.6.415]
39. Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999; 65: 552-561 [PMID: 10340921]
40. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15: 1929-1937 [PMID: 11736724]
41. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211-2221 [PMID: 15917386]
42. Schwab M, Schaeffeler E, Klotz U, Treiber G. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther 2004; 76: 201-209 [PMID: 15371981]
43. Sapone A, Vaira D, Trespidi S, Perna F, Gatta L, Tampieri A, Ricci C, Cantelli-Forti G, Miglioli M, Biagi GL, Paolini M. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. Am J Gastroenterol 2003; 98: 1010-1015 [PMID: 12809821]
44. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129: 1027-1030 [PMID: 9867757]